Biologically Active Small Molecules

An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 &microM).

An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 &microM).

An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 &microM).

An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 &microM).

A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.

A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.

A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.

A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.

A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 &microM.

A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 &microM.

A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 &microM.

A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 &microM.